Publications by authors named "P M Ruz"
The development of effective catalysts for hydrogen (H) generation from chemical hydrides is essential for advancing hydrogen-based energy technologies. Herein, we synthesized a Pd-dispersed CPO-27 catalyst exhibiting exceptional performance for hydrolysis of two boron-based chemical hydrides, i.e.
View Article and Find Full Text PDFArticle Synopsis
- - The study examined gender representation in clinical trials for FDA-approved anticancer drugs from 1998-2018, focusing on participation rates of women compared to men across various cancer types.
- - Findings indicated that women constituted only 40.7% of participants in 148 trials, with significant under-representation in trials for gastric, liver, and lung cancers, while sex-specific efficacy and safety data were rarely reported (only 4% of trials).
- - Despite low female enrollment, there was no correlation between the percentage of women recruited and drug efficacy, highlighting a persistent gap in gender representation in cancer research.
Article Synopsis
- BTK inhibitors are effective for treating B-cell malignancies but are linked to heart issues like atrial fibrillation (AF), the extent and seriousness of which were previously unknown.
- A study monitored B-cell cancer patients on BTK inhibitors from 2009-2020, revealing that 72.4% developed arrhythmias, with 16.3% experiencing new cases of AF and 14.3% showing high AF burden.
- Higher AF burden was correlated with increased risk of major cardiac events and mortality, highlighting the need for careful monitoring and management in patients treated with BTK inhibitors.
H is one of the most attractive fuel alternatives to the existing fossil fuels that cause detrimental environmental issues. Thus, there has been an upsurge in the research on the production of green hydrogen. In this view, cucurbit[7]uril (CB7)-functionalized Co:Ni alloy nanocomposites with different compositions, reported here for the first time, were synthesized to synergise the catalytic activities of a nanoalloy and CB7 and screened for hydrogen generation hydrolysis of ammonia borane (AB).
View Article and Find Full Text PDFCardiovascular toxicities associated with bispecific T-cell engager therapy.
J Immunother Cancer
February 2024
Article Synopsis
- Bispecific T-cell engagers (BTEs) are new treatments for blood cancers, but past studies didn't effectively explore their cardiovascular side effects.
- Using data from the FDA's Adverse Event Reporting System, researchers analyzed cardiovascular adverse events (CVAE) related to five FDA-approved BTEs, discovering a notable incidence and risk of these events.
- The study found that about 20.4% of BTE-related reports involved CVAEs, with significant mortality associated; teclistamab showed the highest risk for severe cardiovascular issues, while blinatumomab was linked to other serious complications.